Perspective Therapeutics (STU:AAJ0) Cyclically Adjusted FCF per Share: €-0.96 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AAJ0 Perspective Therapeutics Inc STU:AAJ0
35 GF Score
Price €2.66
GF Value €0.68
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Perspective Therapeutics Cyclically Adjusted FCF per Share?

Perspective Therapeutics STU:AAJ0 -1.99% 35 Cyclically Adjusted FCF per Share is €-0.96 as of Jun. 2026. GuruFocus rates STU:AAJ0 with a GF Score™ of 35/100 and a GF Value™ of €0.68 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Perspective Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.251. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.96 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -5.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -3.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Perspective Therapeutics was 63.80% per year. The lowest was -5.20% per year. And the median was 5.50% per year.

As of today (2026-08-31), Perspective Therapeutics's current stock price is €2.66. Perspective Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.96. Perspective Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Perspective Therapeutics  (STU:AAJ0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Perspective Therapeutics Cyclically Adjusted FCF per Share Related Terms


Perspective Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Cyclically Adjusted FCF per Share Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.74 -0.84 -0.96 -0.95 -0.89

Perspective Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -0.86 -0.89 -0.94 -0.96

STU:AAJ0 vs VMD, MOBI, RCEL: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Perspective Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:AAJ0
35GF Score
Perspective Therapeutics Inc STU:AAJ0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Perspective Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.251/333.9520*333.9520
=-0.251

Current CPI (Jun. 2026) = 333.9520.

Perspective Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.243 241.428 -0.336
201612 -0.302 241.432 -0.418
201703 -0.261 243.801 -0.358
201706 -0.238 244.955 -0.324
201709 -0.262 246.819 -0.354
201712 -0.248 246.524 -0.336
201803 -0.171 249.554 -0.229
201806 -0.240 251.989 -0.318
201809 -0.224 252.439 -0.296
201812 -0.160 251.233 -0.213
201903 -0.193 254.202 -0.254
201906 -0.141 256.143 -0.184
201909 -0.101 256.759 -0.131
201912 -0.185 256.974 -0.240
202003 -0.121 258.115 -0.157
202006 -0.114 257.797 -0.148
202009 -0.056 260.280 -0.072
202012 -0.081 260.474 -0.104
202103 -0.049 264.877 -0.062
202106 -0.072 271.696 -0.088
202109 -0.128 274.310 -0.156
202112 -0.087 278.802 -0.104
202203 -0.093 287.504 -0.108
202206 -0.200 296.311 -0.225
202209 -0.132 296.808 -0.149
202212 -0.291 296.797 -0.327
202303 -0.405 301.836 -0.448
202306 -0.284 305.109 -0.311
202309 -0.345 307.789 -0.374
202312 -0.297 306.746 -0.323
202403 0.089 312.332 0.095
202406 -0.138 314.175 -0.147
202409 -0.336 315.301 -0.356
202412 -0.556 315.605 -0.588
202503 -0.335 319.799 -0.350
202506 -0.245 322.561 -0.254
202509 -0.210 324.800 -0.216
202512 -0.342 324.054 -0.352
202603 -0.320 330.213 -0.324
202606 -0.251 333.952 -0.251

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.96 mean?
Perspective Therapeutics (STU:AAJ0) has a Cyclically Adjusted FCF per Share of €-0.96 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Cyclically Adjusted FCF per Share too high?
Perspective Therapeutics' current Cyclically Adjusted FCF per Share is €-0.96. Overall, Perspective Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Cyclically Adjusted FCF per Share compare to VMD and MOBI?
Perspective Therapeutics' Cyclically Adjusted FCF per Share of €-0.96 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current Cyclically Adjusted FCF per Share is €-0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Perspective Therapeutics (STU:AAJ0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.68, compared to a current price of €2.66 — trading 291.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.96. Perspective Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Perspective Therapeutics (STU:AAJ0), the current Cyclically Adjusted FCF per Share is €-0.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Perspective Therapeutics (STU:AAJ0) Overvalued in 2026?

Based on GuruFocus' analysis, Perspective Therapeutics stock appears to be overvalued. The current stock price of €2.66 is trading 291.2% above its estimated GF Value™ of €0.68. GuruFocus considers Perspective Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:AAJ0:

  • Cyclically Adjusted FCF per Share: €-0.96
  • GF Value™: €0.68 vs. price of €2.66 (291.2% above fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the STU:AAJ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Perspective Therapeutics Business Description

Other Exchanges CATX:USAAAJ0:Germany
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
35GF Score

Get the complete analysis for STU:AAJ0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€0.68
GF Value